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Abstract
Background: Obesity and Type 2 diabetes have reached epidemic status worldwide. Wild lowbush blueberry
(Vaccinium angustifolium Aiton) is a plant of the North American Aboriginal traditional pharmacopeia with antidiabetic
potential, especially when it is fermented with Serratia vaccinii.
Methods: A phytochemical fractionation scheme was used to identify potential bioactive compounds as confirmed by
HPLC retention times and UV–Vis spectra. 3 T3-L1 cells were differentiated for 7 days with either Normal Blueberry
Extract (NBE), Fermented Blueberry Extract (FBE/F1), seven fractions and four pure compounds. Triglyceride content was
measured. Examination of selected intracellular signalling components (p-Akt, p-AMPK) and transcriptional factors
(SREBP-1c and PPARγ) was carried out by Western blot analysis.
Results: The inhibitory effect of FBE/F1 on adipocyte triglyceride accumulation was attributed to total phenolic (F2)
and chlorogenic acid enriched (F3-2) fractions that both inhibited by 75%. Pure compounds catechol (CAT) and
chlorogenic acid (CA) also inhibited adipogenesis by 70%. Treatment with NBE, F1, F3-2, CAT and CA decreased
p-AKT, whereas p-AMPK tended to increase with F1. The expression of SREBP1-c was not significantly modulated.
In contrast, PPARγ decreased in all experimental groups that inhibited adipogenesis.
Conclusions: These results demonstrate that fermented blueberry extract contains compounds with anti-adipogenic
activity, which can serve to standardize nutraceutical preparations from fermented blueberry juice and to develop
novel compounds with anti-obesity properties.
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Background
According to the WHO, global estimates of obesity rates
in 2014 showed that more than 1.9 billion adults were
overweight whereas 600 million were experiencing obesity
[1]. Similar to many countries, Canada has experienced a
substantial increase in the prevalence of obesity [2, 3].
Obesity and Type 2 diabetes have increased especially in
Canadian Aboriginal populations. A report by the Organ-
isation for Economic Co-operation and Development
suggested that in some countries, including Canada, the
prevalence of obesity will continue to rise at a predicted
rate of 4–5% per year [2].
Adipocyte differentiation, or adipogenesis, implicates
the accumulation of cellular lipid and is regulated by
genetic and growth factors as well as hormones, notably
by insulin [4]. Insulin is a major anabolic regulator of
energy homeostasis and its signalling pathways implicate
the serine/threonine-specific protein kinase Akt. Knockout
models of the different Akt isoforms (Akt1 and Akt2)
demonstrated their essential role in regulating adipogene-
sis [5] as well as glucose metabolism in the body [6]. Thus,
Akt can drive adipogenesis. Its role includes the phos-
phorylation and regulation of a large number of substrates
involved in several biological processes [7]. Adipocyte
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differentiation is also mediated by the temporally modu-
lated expression of several transcription factors, notably
PPARγ (peroxisome-proliferator-activated receptor gamma)
that is a key regulator of this transcriptional program [8].
Another important enzyme involved in fat metabolism
is the insulin-independent AMP-activated protein kinase
(AMPK). It acts as a metabolic master switch regulating
several intracellular systems, including the cellular uptake
of glucose, the β-oxidation of fatty acids and mitochon-
drial biogenesis, which appear highly sensitive to energy
status. Upon activation, AMPK increases cellular energy
levels by inhibiting anabolic pathways (fatty acid synthesis,
protein synthesis) and stimulating catabolic pathways
(fatty acid oxidation, glucose transport) [9].
The use of natural health products as complementary
or alternative approaches to existing medications is grow-
ing in popularity for the treatment and management of
obesity and related diseases such as type 2 diabetes. Nat-
ural and synthetic agents can exert anti-obesity effects by
increasing lipolysis in white adipocytes and by blocking
adipocyte differentiation [10]. Notably, fermented blue-
berry extract was previously shown to inhibit triglyceride
accumulation during adipogenesis of 3 T3-L1 cells [11],
which could constitute a potential anti-obesity action.
Such bio-transformed blueberry extract was also found to
contain a much higher content in total phenolics and it
was able to increase AMPK phosphorylation and glucose
uptake in muscle cells and adipocytes [11, 12]. However,
the compounds responsible for these effects still remain
unclear, as does the participation of Akt in this process.
Consequently, the principal aim of this study was to
identify potential bioactive components of fermented wild
blueberry extract using 3 T3-L1 cells. For this purpose, we
carried out phytochemical fractionation of fermented
blueberry extract to generate semi-purified fractions and
isolate active compounds that could be responsible for the
observed inhibitory effect on adipogenesis. We also began
addressing the potential molecular mechanisms that could
underlie such an anti-adipogenic action by assessing the
protein expression of selected key regulatory elements.
Methods
Chemicals and biochemicals
Dexamethasone (DXM), bovine pancreatic insulin, 3-
isobutyl-1-methylxanthine (IBMX), dimethyl sulfoxide
(DMSO) were purchased from Sigma-Aldrich. Rosigli-
tazone came from Alexis Biochemicals (Hornby, ON).
Dulbecco’s Modified Eagle Medium was from Wisent
Inc. (St-Bruno, QC). For the measurement of triglyceride
content, the AdipoRed reagent was used (Lonza Walkers-
ville Inc., Walkersville, MD). We also used the Western
Lightning ECL from Perkin Elmer (Waltham, MA).
Aminoimidazole carboxamide ribonucleotide (AICAR) was
purchased from Toronto Research Chemicals (Toronto,
ON). The measurement of protein was carried out with an
assay kit from Bio-Rad (Mississauga, ON).
Preparation of wild blueberry extract
Frozen wild blueberry fruit (Vaccinium angustifolium
Aiton) was obtained from Oxford Frozen Foods Ltd
(Oxford, NS). It represents a uniform blend of a large
number of genotypes coming from several producers in
Northeastern United States and Canada. In this respect,
it accurately reflects the material that is normally used to
prepare commercial wild blueberry juice. Notwithstand-
ing, our laboratory analysis has confirmed that cultivar
types do not affect the fermentation profile significantly.
The extract was prepared by blending such wild blue-
berry fruit (100 g) with an equivalent quantity (100 g) of
Minimal Broth Davis without dextrose (MM) (Difco La-
boratories, Detroit, MI). The preparation was centrifuged
to remove insoluble particles. The resulting extract was
sterilized using 0.22 μm Express Millipore filter (Millipore,
Etobicoke, ON) and fermented with Serratia vaccinii bac-
teria as described [12]. Normal blueberry extract (NBE)
was processed in an identical manner but was not fermen-
ted with the bacteria. Portions of NBE and the fermented
blueberry extract (FBE) were freeze-dried and used for
chemical analysis.
Phytochemical fractionation of FBE
Fractions were prepared by a multi-step process (Table 1)
that started with material that was either NBE or NBE
after fermentation with Serratia vaccinii to produce FBE.
As a first fractionation step, FBE (identified as F1; Table 1)
was loaded in batches of 500 ml onto 29.5 × 5 cm chro-
matography columns (pre-conditioned with 1 column
volume of methanol then 2 column volumes of water)
containing Waters preparative C18 resin (125 Å, 55–
105 μm). These were washed with 2 column volumes of
water to remove sugars and organic acid (discarded).
Phenolic compounds were eluted from the column using
1.2 column volumes of 100% ethanol containing 13 mM
trifluoroacetic acid (Sigma Aldrich, ON). This ethanol
eluent, which contained all the phenolics from the FBE
starting material, was dried using rotary evaporation and
lyophilisation. This total phenolic fraction from FBE was
called F2.
For the second fractionation step of the FBE, one por-
tion of F2 was dissolved in water and applied to another
preconditioned C18 column to generate Fraction F3-1
that contained low MW phenolic compounds. This was
done by selective elution using 4 column volumes of
aqueous 2.06 M (12.5%) ethanol containing 0.16 M HCl
(Ricca Chemical Company, Arlington, TX). F3-1 com-
pounds recovered in this step were identified by HPLC
by comparing retention times and UV–Vis profiles of
the peaks to pure standards. The next fraction, called
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F3-2, was produced by passing through the same C18
column an additional 2 column volumes of aqueous
2.06 M (12.5%) ethanol containing 0.16 M HCl. This
F3-2 fraction was rich in chlorogenic acid, which was
confirmed by HPLC. The remaining bound materials
were eluted using 0.16 M HCl and 13.7 M (80%) ethanol in
water to produce fraction F3-3 (Table 1). The F3-1, F3-2
and F3-3 fractions were dried using rotary evaporation and
then freeze dried.
To produce three additional and final fractions, one
portion of F3-3 was dissolved in 4.28 M (25%) ethanol
and applied to a 34.5 × 5 cm column of Sigma-Aldrich
lipophilic Sephadex LH-20 (25–100 μm). The first fraction
from Sephadex LH-20 was obtained by washing with 7
column volumes of 4.28 M (25%) ethanol. This fraction,
called F4-1, was enriched in anthocyanins. The same
Sephadex LH20 column was then washed with 3 column
volumes of 8.56 M (50%) ethanol to yield a fraction
enriched in phenolic heteropolymers and called F4-2. The
last Sephadex LH20 fraction was eluted using 3 column
volumes of 9.53 M (70%) acetone. This fraction was
enriched in proanthocyanidins and called F4-3. The three
fractions obtained from the Sephadex LH20 column
(F4-1, F4-2 and F4-3) were dried using rotary evaporation
and lyophilisation. All fractions were examined on HPLC
and four pure compounds of interest were identified,
namely catechol (CAT), protocatechuic acid (PA), gallic
acid (GA) and chlorogenic acid (CA), which were subse-
quently purchased from Sigma-Aldrich (Oakville, ON).
Cell culture
Murine 3 T3-L1 pre-adipocyte cells were obtained from
ATCC (Manassas, VA) and used between passages 5 and
8. They were grown in Dulbecco’s modified Eagle’s
medium (DMEM), containing 10% bovine calf serum until
confluent at 100%. Two days after confluence (Day 0), the
cells were stimulated to differentiate with DMEM contain-
ing 10% fetal bovine serum (FBS), 500 nM insulin, 1 μM
Dexamethasone and 250 μM IBMX for 2 days (Day 2)
(Short Term Medium). Cells were maintained in 10%
FBS/DMEM with 500 nM insulin for another 4 days
(Long Term Medium) at which time >90% of wells
showed mature adipocytes with accumulated fat droplets.
Cells were maintained at 37 °C in a humidified 5% CO2
atm and differentiated for a total of 7 days with media
change every 2 days.
Evaluation of cytotoxicity
Cell viability was assed through a Cytotoxicity Detection
Kit that was purchased from Roche (South San Francisco,
CA). 3 T3-L1 pre-adipocytes were seeded in 24-well plates
and cultured to 100% confluence in culture medium and
treated for 7 days as described above with various compo-
nent concentrations (5, 10 and 15 μg/ml of NBE, FBE/F1,
specific fractions and pure compounds). Cell culture media
for each condition were collected separately (released
LDH) and then cells were lysed with culture medium con-
taining 1% Triton X-100, for 10 min (intracellular LDH).
All samples were collected in Eppendorf tubes and centri-
fuged at 250xg at 4 °C for 10 min. Fluorescence was mea-
sured (Wallac Victor2, Perkin-Elmer, Waltham, MA) at an
emission wavelength of 590 nm. Results were expressed as
the ratio of released LDH to total LDH (intracellular plus
released), normalized to values obtained from cells treated
with the vehicle control (0.1% DMSO). The optimal con-
centration was determined for each tested component and
used for bioassays.
Adipogenesis assay
NBE, FBE (F1), specific fractions (5 μg/ml), four pure
compounds at 5 μg/ml (except catechol at 3 μg/ml), and
rosiglitazone (10 μM; positive control) were dissolved in
DMSO and added to the cells as of day 0 of differenti-
ation. The final concentration of DMSO was kept at
0.1% throughout the differentiation period. Adipogenesis
was assessed in the well-characterized 3 T3-L1 cell
model by measuring the accumulation of triglycerides
upon differentiation after treatments as described previ-
ously [13, 14], using the AdipoRed reagent according to
the manufacturer’s instructions. Briefly, after washing
Table 1 Fractionation of fermented blueberry extract (F1). The major component (s) in each fraction (F) are indicated
Fraction Major component (s) Starting material Column resin Eluant
F1
(FBE)
Sugars, organic acids, growth media, phenolics
F2 phenolics F1 C18 EtOH
F3-1 Gallic acid, catechol, protocatechuic acid F2 C18 12% EtOH
F3-2 Chlorogenic acid F2 C18 12% EtOH
F3-3 Flavonoids F2 C18 80% EtOH
F4-1 Anthocyanins F3-3 LH20 25% EtOH
F4-2 Heteropolymers F3-3 LH20 50% EtOH
F4-3 Proanthocyanidins F3-3 LH20 70% EtOH
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each well twice with phosphate-buffered saline (PBS:
8.1 mM Na2HPO4, 1.47 mM KH2PO4, 137 mM NaCl,
and 2.68 mM KCl; pH 7.4), 2 ml of PBS 1X containing
60 μl of AdipoRed reagent were added to each well and
incubated for 10 min at room temperature. Fluorescence
was measured (Wallac Victor2, Perkin-Elmer, Waltham,
MA) at 485 nm excitation and 572 nm emission wave-
lengths. Results are reported as a percentage of the value
obtained for the vehicle control (0.1% DMSO).
Western blot analysis
Cells were cultured, treated and differentiated as described
above for the adipogenesis assay. Cultured cells were ho-
mogenized in lysis buffer (50 mmol/L HEPES, pH 7.4,
150 mmol/L NaCl 5 mmol/L EGTA, 2 mmol/L MgCl2, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS) con-
taining protease inhibitors (2 mmol/L PMSF and Complete
Mini-EDTA-free protease inhibitor cocktail tablets; Roche,
Laval, QC) and phosphatase inhibitors (0.5 mmol/L NaF,
2 mmol/L Na3VO4, 1 mmol/L Na4P2O7). The protein con-
centration of lysates was assessed by the Bradford colori-
metric assay and 40 μg of total protein were loaded onto a
12% acrylamide gel. Samples were electro-transferred to
nitrocellulose membrane (Bio-Rad Laboratories, Hercules,
CA). Membranes were incubated overnight with primary
antibodies to Akt and p-Akt, (1:250, Cell Signalling
Technology, Danvers, MA) as well as p-AMPK, AMPK,
SREBP-1c and PPARγ (1:250, Santa Cruz Biotechnology
Inc., Dallas, TX) and beta-actin (1:1000, Cell Signalling
Technology Inc., Danvers, MA). Incubation with anti-
rabbit HRP-conjugated secondary antibody (Cell Signalling
Technology Inc., Danvers, MA) was then carried out at
1:20000 dilution in TBST (1X) (50 mmol/L Tris, pH 7.4,
150 mmol/L NaCl, 0.5% Tween 20) plus 5% non-fat dried
milk for 1 h at room temperature. Membranes were
then washed with TBST 3X for 5 min and the blots
were revealed using the Western Lightning ECL enhanced
chemiluminescence (Enhanced Chemiluminescence Sub-
strate for 1000 cm2 of membrane). Densitometry analysis
was performed with General Electric Image Quant LAS
4000 mini scanner and Image J software (GE Healthcare
Bio Sciences, Baie d’Urfé, QC).
Statistical analysis
Results are presented as the mean ± SEM of 3 independent
experiments carried out in triplicate. Statistical analysis
was performed with Prism GraphPad software (La Jolla,
CA). The data were analyzed by one-way analysis of
variance (ANOVA) followed by Dunnett’s and/or Tukey’s
multiple comparison test for statistically significant differ-
ences between groups, as appropriate. Statistical signifi-
cance was set at a level of p < 0.05.
Results
Phytochemical fractionation scheme and selection of pure
compounds
Using a C18 column with varying ethanol and acid con-
centrations, sugars and organic acids were removed and
several fractions were obtained as illustrated in Fig. 1
and listed in Table 1. This fractionation scheme was used
Fig. 1 HPLC profile (280 nm) of fermented blueberry extract indicating the major components contained in fractions (see also Table 1)
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previously to study the effect of NBE components on
cardiomyocyte integrity [15] and was applied to FBE as
a practical approach. Based on HPLC profiles (Fig. 1),
fractions containing phenolic compounds (F2), whose
sub-fractions contained gallic acid (GA), catechol (CAT)
and protocatechuic acid (PA) (Fraction F3-1) as well as
chlorogenic acid (CA) (Fraction 3-2), were of greatest
interest [15].
Cell viability
Figure 2 presents the results of the LDH cytotoxicity
assay. NBE and FBE as well FBE fractions and pure
compounds were tested at 5, 10 and 15 μg/ml. As can
be appreciated, NBE and FBE crude preparations induced
LDH leakage that was similar to the DMSO control at
concentrations of 5 and 10 μg/ml. In contrast, the optimal
concentrations of other fractions and pure compounds
were 5 μg/ml (except catechol at 3 μg/ml). In order to
compare the various preparations at similar per weight
contents, we also tested NBE and FBE at 5 μg/ml. Cells
did not exhibit damage in response to such concentrations
of test substances and were morphologically comparable
to cells treated with the vehicle control 0.1% DMSO (data
not illustrated). These concentrations were thus used
subsequently for all in vitro assays.
Adipogenesis assay
The amount of accumulated triglycerides was measured
on day 7 in 3 T3-L1 cells treated with the specified con-
centrations of NBE, F1 and its specific fractions, as well
as CAT, CA, PA and GA (7 fractions and 4 pure com-
pounds). As illustrated in Fig. 3, only certain fractions of
F1 were able to significantly inhibit TG accumulation.
Notably, fractions F2 and F3-2 reduced triglyceride ac-
cumulation to 25 and 30% as compared to the vehicle
control (set at 100%), respectively. Similarly, only two
of the four pure compounds exerted a significant anti-
adipogenic effect. Indeed, CA and CAT yielded adipo-
genic values that were 75 and 70% lower than DMSO.
Western blot analysis
Fractions and pure compounds with significant anti-
adipogenic effect, namely F2, F3-2, CAT and CA, were ana-
lyzed by Western blot for cellular components involved in
the control of adipogenesis and were compared with NBE
and FBE (F1). As shown in Fig. 4a, all treatments that inhib-
ited adipogenesis also decreased the phosphorylation of the
insulin-dependent kinase Akt, with CA having the most
prominent effect. In contrast, the phosphorylation of the
insulin-independent kinase AMPK was not significantly
affected by any of the treatments, albeit F1 had a tendency
to increase it relative to vehicle control (Fig. 4b).
Fig. 2 Lack of toxicity of optimal concentrations of fermented blueberry extract and components. 3 T3-L1 pre-adipocytes were seeded at a density of
2 × 104 cells, cultured to 100% confluence and treated for 7 days with treatments as described above. Cytotoxicity was measured by LDH leakage.
Medium LDH activity was expressed as a percentage of total enzyme activity (medium+ lysate). The results are shown as the mean ± SEM. Significant
differences compared to DMSO vehicle control were assessed by one way ANOVA; post hoc analysis with Dunnett’s multiple comparison test.
*** Denotes statistically significant from vehicle control (p < 0.001)
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We next examined two selected key adipocyte-
associated transcription factors. As illustrated in Fig. 5b,
SREBP-1c was not significantly affected by any of the
treatments. Conversely, all treatment conditions that sig-
nificantly reduced adipogenesis, namely F2, F3-2, CAT
and CA, markedly decreased the expression of PPARγ as
compared to the vehicle control (Fig. 5a). As expected, the
positive control Rosiglitazone significantly increased
PPARγ expression (Fig. 5a).
Discussion
Research in obesity is increasingly focusing on adipose
tissue and adipogenesis. Indeed, adipose tissue appears
to be involved with the development of the metabolic
syndrome [16]. Food and medicinal plants are important
sources of natural products that display great chemical
diversity. This makes them excellent candidates for drug
development, including for the treatment of obesity and
other related diseases [17]. We previously observed that
the fermentation of the juice from wild lowbush blue-
berries (Vaccinium angustifolium Aiton), with a bacteria
(Serratia vaccinii) found on the fruit skin, was able to
greatly increase the total phenolic content [12]. This bio-
transformation also conferred it potent anti-diabetic
properties [11]. In the latter study, we also uncovered an
inhibitory action of fermented blueberry juice on 3 T3-L1
adipogenesis, representing a putative anti-obesity action
that was later confirmed in vivo [18]. In the present study,
we sought to determine the biologically active compounds
that could underlie such anti-adipogenic effects. We used
an HPLC-based fractionation scheme that provided us
with several fractions focused primarily on phenolic
components. We notably identified four major compounds,
namely gallic acid, catechol, protocatechuic acid and
chlorogenic acid, which we also tested. We used the
3 T3-L1 cell line, one of the most reliable models for
the study of adipogenesis [19].
Fig. 3 Fermented blueberry extract and fractions inhibit adipogenesis.
3 T3-L1 pre-adipocytes were seeded at a density of 2 × 104 cells,
cultured to 100% confluence and treated for 7 days with indicated
treatments as described in Materials and Methods. Rosiglitazone
was used as a positive control inducing differentiation (10 μM).
DMSO 0.1% was used as vehicle control. The results are shown as
the mean ± SEM. Significant differences compared to DMSO vehicle
control were assessed by one-way ANOVA; post hoc analysis with
Dunnett’s multiple comparison test. *Denotes statistically significant
from vehicle control (p < 0.05). **Denotes statistically significant from
vehicle control (p < 0.01). ***Denotes statistically significant from
vehicle control (p < 0.001)
Fig. 4 Effects of FBE and specific fractions on the phosphorylation of insulin-dependent Akt a and insulin-independent AMPK b. 3 T3-L1 preadipocytes
were incubated with DMSO (0.1%) or 5 μg/ml of NBE, fractions F1, F2, F2-3 and two pure compounds CAT (3 μg/ml), CA (5 μg/ml) and induced to
differentiate. The expression levels of key signalling proteins were measured after treatments by Western blot analysis; p-Akt, Akt a p-AMPK,
AMPK b. Results are shown as the mean ± SEM. Significantly different compared to DMSO control *p < 0.05, **p < 0.01
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As a first step, we freeze dried the fermented blueberry
juice and the resulting extract, called F1, had a tendency
to inhibit adipogenesis, albeit not to the extent that the
intact fermented blueberry juice had done previously
[11]. This may be explained by the different concentra-
tions used in the two studies. In our previous study, in-
tact fermented blueberry juice was administered to cells
at a dose of total phenolics equivalent to 30 μM of gallic
acid (GAE) [11]. In the present studies, we used FBE/F1
at the same weight-based concentration found to be opti-
mal for the phytochemical fractions and pure compounds,
in order to have a valid comparison. This concentration
(5 μg/ml) amounts to 1.6 μM GAE, when the total phen-
olic content of FBE was taken into consideration. It is
therefore almost 20 times less concentrated than that used
in our previous study [11]. More surprisingly, when NBE
was subjected to a similar freeze-drying step, it was found
to also have a non-significant tendency to reduce adipo-
genesis. This was different than what was observed in our
previous study, where NBE was without effect [11]. Fur-
ther studies will be necessary to understand the potential
effect of freeze-drying on the phytochemical composition
of wild lowbush blueberry juice, notably in the context
of adipogenesis. Indeed, other researchers, using culti-
vated highbush blueberry phenolics, have observed a
concentration-dependent inhibition of adipogenesis in
the 3 T3-F44A cell line [20].
Notwithstanding, we found that two sub-fractions of
our fermented blueberry extract exhibited a significant
inhibition of adipogenesis. The first, F2, was the fraction
that contained all the phenolic compounds while the
second, F3-2, was enriched in chlorogenic acid. This was
confirmed by the corresponding activity of the pure com-
pound (chlorogenic acid). Of the other pure compounds,
only catechol was found to also inhibit adipogenesis sig-
nificantly. This implies that chlorogenic acid and catechol
may contribute to the anti-obesogenic potential of fer-
mented blueberry juice.
We next began assessing some of the potential molecu-
lar mechanisms that can underlie the anti-adipogenic ac-
tivity of fermented blueberry juice. Adipogenesis involves
a complex and coordinated transcriptional cascade that
leads to lipogenesis and TG accumulation [21, 22].
Insulin-dependent Akt signalling can trigger this cascade
[5–7]. In contrast, insulin-independent AMPK signalling
can inhibit adipogenesis [11]. In line with the inhibitory
effect of fermented blueberry juice and its components,
we found that F1 as well as sub-fractions F2 and F3-2 sig-
nificantly inhibited the phosphorylation of Akt. This result
is in line with the report by Song and collaborators who
studied blueberry peel extracts and found an anti-
adipogenic effect that was related to the inhibition of
Akt phosphorylation [23].
On the other hand, F1 had a tendency to increase
AMPK, although this effect failed to reach statistical sig-
nificance. This implies that fermented blueberry prod-
ucts may diminish adipogenesis principally by reducing
insulin-dependent signalling. Interestingly, our previous
work had shown that fermented blueberry juice could
stimulate AMPK in 3 T3-L1 adipocytes, an effect that
Fig. 5 Effects of FBE and specific fractions on the expression of adipogenesis-related transcription factors. 3 T3-L1 preadipocytes were incubated
with DMSO (0.1%) or 5 μg/ml of NBE, fractions F1, F2, F2-3 and pure compounds CAT (3 μg/ml), CA (5 μg/ml) and induced to differentiate. PPARγ a
and SREBP-1c b expression levels were examined by Western blot. Protein expressions were normalized using β-actin as a reference. Results are shown
as the mean ± SEM. Significantly different compared to DMSO control *p < 0.05, **p < 0.01
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was implicated in the stimulation of glucose transport
observed in the same cells [11]. The implication of
AMPK in the inhibition of adipogenesis by fermented
blueberry juice may be less critical at the concentration
used in the present studies.
The adipogenic process is a complex and highly regu-
lated program of gene expression that involves several
key transcription factors that include SREBP-1c and PPARγ
[19, 24]. We therefore chose to determine the protein
content of these two transcription factors as an initial
step to assess potential underlying molecular mechanisms.
Although treatment with sub-fractions F2 and F2-3 as well
as pure compounds CAT and CA failed to significantly
modulate SREBP-1c protein expression, they all had a ten-
dency to reduce it. However, SREBP-1c is activated early
in the transcriptional cascade such that our assessment
near the end of adipogenesis may explain the low vari-
ations in protein expression that we observed. More
detailed studies, including time-course and mRNA as-
sessments will be necessary to verify the potential role
of SREBP-1c in the effects of FBE on adipogenesis.
In contrast, the results of the current studies clearly
show that the same active components of fermented
blueberry juice induced a strong inhibition of PPARγ.
Our results thus suggest that the negative modulation of
PPARγ may be involved in the anti-adipogenic action of
fermented blueberry juice. This is similar to what was
observed by Song and collaborators, where blueberry peel
extracts significantly reduced PPARγ [23]. Nevertheless,
more detailed studies, notably addressing the modulation
of the gene expression of several components controlling
adipogenesis, will be necessary to confirm this point and
determine if other factors than PPARγ are involved.
It is well known that a high phenolic content in the
diet is associated with the prevention of certain chronic
diseases, whereas phenolic acids have demonstrated anti-
oxidant and anti-inflammatory properties [25]. Indeed,
chlorogenic acid, a major component of green bean cof-
fee extract, has been reported to reduce blood sugar
levels and potentially exert an anti-diabetic effect [26]. It
has also been implicated in weight loss in humans [27, 28]
and recently shown to stimulate lipolysis in adipocytes in
culture [29, 30].
The present studies suggest that chlorogenic acid may
also exert its anti-obesity potential through the inhib-
ition of adipocyte Akt phosphorylation and of the down-
stream transcription factor PPARγ, a major regulator of
adipogenesis. On the other hand, catechol is a simple
polyphenol found in a wide variety of plants. In the
present studies, it was also found to significantly diminish
adipogenesis through mechanisms involving an inhibition
of Akt phosphorylation and a reduction in PPARγ. To our
knowledge, this is the first instance where such biological
activity has been reported for catechol.
Conclusions
We identified chlorogenic acid and catechol as active
components of fermented blueberry juice. These com-
pounds can serve to further develop the potential of this
fermented juice as a novel nutraceutical. Both compounds
can also serve as templates for the development of novel
alternative therapeutic agents against obesity and related
diseases.
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